Bristol Vanlev Second-Line Hypertension Use To Be Reviewed By FDA Cmte.
Executive Summary
Bristol-Myers Squibb will ask an FDA advisory committee to recommend Vanlev for a second line hypertension indication, Exec VP Donald Hayden told the Goldman Sachs healthcare conference June 13 in Laguna Niguel, Calif